CAMBRIDGE, Mass.– Nvelop Therapeutics, a biotechnology company engineering programmable, non-viral vehicles for the in vivo delivery of therapeutic cargo, today announced the presentation of new preclinical data from its DLVR-M platform at the 27th annual meeting of the American Society of Gene & Cell Therapy (ASGCT) in Baltimore. These data are the first from its DLVR-M platform, one of Nvelop’s two in vivo-validated platforms currently being developed to enable efficient and cell-specific delivery of a broad set of therapeutic cargoes to treat a wide range of genetic diseases.
The DLVR-M platform was developed at Massachusetts General Hospital by gene editing pioneer J. Keith Joung, M.D., Ph.D., and uses modular particles with few or no viral proteins to deliver a broad range of therapeutic cargoes in vivo. These cargoes can include CRISPR, base editor, and prime editor ribonucleoproteins. DLVR-M has a distinct mechanism for loading cargoes within the particles, which does not rely on viral-derived proteins.
“We are excited to share the first in vivo data on our DLVR-M platform to further illustrate the breadth and diversity of the highly innovative delivery technologies we are developing,” said Jeff Walsh, Nvelop’s Chief Executive Officer. “This represents an important advance for the delivery of genetic medicines with intricately engineered particles that have the potential to be fully humanized. We believe this platform will further our aim of advancing new technologies that increase delivery efficiency, tissue specificity and cargo diversity, and that address safety challenges seen in some of today’s in vivo platforms.”
